Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.
Identifieur interne : 000157 ( Main/Exploration ); précédent : 000156; suivant : 000158Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.
Auteurs : Quentin Canelle [Belgique] ; Walthère Dewé [Belgique] ; Bruce L. Innis [Belgique] ; Robbert Van Der Most [Belgique]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.
Descripteurs français
- KwdFr :
- Affinité des anticorps, Anticorps antiviraux (sang), Enfant, Enfant d'âge préscolaire, Europe, Femelle, Glycoprotéine hémagglutinine du virus influenza (immunologie), Grippe humaine (), Humains, Immunoglobuline G (immunologie), Liaison aux protéines, Mâle, Protéines recombinantes (immunologie), Québec, Résonance plasmonique de surface, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Glycoprotéine hémagglutinine du virus influenza, Immunoglobuline G, Protéines recombinantes, Vaccins antigrippaux.
- sang : Anticorps antiviraux.
- Affinité des anticorps, Enfant, Enfant d'âge préscolaire, Europe, Femelle, Grippe humaine, Humains, Liaison aux protéines, Mâle, Québec, Résonance plasmonique de surface.
English descriptors
- KwdEn :
- Antibodies, Viral (blood), Antibody Affinity, Child, Child, Preschool, Europe, Female, Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans, Immunoglobulin G (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Male, Protein Binding, Quebec, Recombinant Proteins (immunology), Surface Plasmon Resonance.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Hemagglutinin Glycoproteins, Influenza Virus, Immunoglobulin G, Influenza Vaccines, Recombinant Proteins.
- prevention & control : Influenza, Human.
- Antibody Affinity, Child, Child, Preschool, Europe, Female, Humans, Male, Protein Binding, Quebec, Surface Plasmon Resonance.
Abstract
In retrospective observational studies, an increased relative risk of incident narcolepsy was observed in some European countries among recipients of the AS03-adjuvanted, A(H1N1)pdm09, inactivated, detergent-split virion vaccine Pandemrix™ manufactured in Dresden, Germany (D-Pan H1N1). A similar increased risk was not observed in a retrospective population-based study in individuals in Quebec province, Canada, who received Aprepanrix™, a Quebec-manufactured AS03-adjuvanted A(H1N1)pdm09 inactivated, detergent-split virion vaccine (Q-Pan H1N1). Antibody responses in D-Pan versus Q-Pan vaccinees (adults/children) measured as hemagglutination inhibition (HI) titers 21 d post-vaccination were found to be equivalent (NCT01161160). The current post-hoc analysis was conducted to determine whether antibody avidity differed following immunization with the 2 vaccines. Using surface plasmon resonance, we evaluated the capacity of serum specimens (drawn from the comparative immunogenicity trial) from a subset of subjects aged 3-9 y who received either D-Pan or Q-Pan (N = 28/group), to bind to recombinant A(H1N1)pdm09 hemagglutinin. IgG antibodies were purified from Day 21 sera. Binding was assessed by end association level; dissociation by retention of antigen-antibody complexes at the end of the dissociation phase, and kd. Inter-run variability for the control monoclonal antibody, association levels and dissociation levels was low (CVs 1.3%, 7.8% and 1.4%, respectively); non-specific binding was negligible. High avidity and slow dissociation was observed for both groups (kd ≤ 10(-4)/s; geometric mean [IQR] association and dissociation levels for D-Pan/Q-Pan: 15.4 RU [13.4-17.7]/12.4 RU [10.8-14.3] and 94.5% [92.5-96.5]/95.5% [93.5-97.6], respectively). Association, but not dissociation levels correlated with HI titers. No significant differences in avidity parameters were observed between D-Pan and Q-Pan sera.
DOI: 10.1080/21645515.2016.1168954
PubMed: 27105343
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.</title><author><name sortKey="Canelle, Quentin" sort="Canelle, Quentin" uniqKey="Canelle Q" first="Quentin" last="Canelle">Quentin Canelle</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author><author><name sortKey="Dewe, Walthere" sort="Dewe, Walthere" uniqKey="Dewe W" first="Walthère" last="Dewé">Walthère Dewé</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author><author><name sortKey="Innis, Bruce L" sort="Innis, Bruce L" uniqKey="Innis B" first="Bruce L" last="Innis">Bruce L. Innis</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author><author><name sortKey="Van Der Most, Robbert" sort="Van Der Most, Robbert" uniqKey="Van Der Most R" first="Robbert" last="Van Der Most">Robbert Van Der Most</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27105343</idno><idno type="pmid">27105343</idno><idno type="doi">10.1080/21645515.2016.1168954</idno><idno type="wicri:Area/Main/Corpus">000147</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000147</idno><idno type="wicri:Area/Main/Curation">000147</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000147</idno><idno type="wicri:Area/Main/Exploration">000147</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.</title><author><name sortKey="Canelle, Quentin" sort="Canelle, Quentin" uniqKey="Canelle Q" first="Quentin" last="Canelle">Quentin Canelle</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author><author><name sortKey="Dewe, Walthere" sort="Dewe, Walthere" uniqKey="Dewe W" first="Walthère" last="Dewé">Walthère Dewé</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author><author><name sortKey="Innis, Bruce L" sort="Innis, Bruce L" uniqKey="Innis B" first="Bruce L" last="Innis">Bruce L. Innis</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author><author><name sortKey="Van Der Most, Robbert" sort="Van Der Most, Robbert" uniqKey="Van Der Most R" first="Robbert" last="Van Der Most">Robbert Van Der Most</name><affiliation wicri:level="1"><nlm:affiliation>a GSK Vaccines , Rixensart , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a GSK Vaccines , Rixensart </wicri:regionArea><wicri:noRegion>Rixensart </wicri:noRegion></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (blood)</term><term>Antibody Affinity</term><term>Child</term><term>Child, Preschool</term><term>Europe</term><term>Female</term><term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term><term>Humans</term><term>Immunoglobulin G (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Protein Binding</term><term>Quebec</term><term>Recombinant Proteins (immunology)</term><term>Surface Plasmon Resonance</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Affinité des anticorps</term><term>Anticorps antiviraux (sang)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Europe</term><term>Femelle</term><term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term><term>Grippe humaine ()</term><term>Humains</term><term>Immunoglobuline G (immunologie)</term><term>Liaison aux protéines</term><term>Mâle</term><term>Protéines recombinantes (immunologie)</term><term>Québec</term><term>Résonance plasmonique de surface</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Immunoglobulin G</term><term>Influenza Vaccines</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Immunoglobuline G</term><term>Protéines recombinantes</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antibody Affinity</term><term>Child</term><term>Child, Preschool</term><term>Europe</term><term>Female</term><term>Humans</term><term>Male</term><term>Protein Binding</term><term>Quebec</term><term>Surface Plasmon Resonance</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Affinité des anticorps</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Europe</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Liaison aux protéines</term><term>Mâle</term><term>Québec</term><term>Résonance plasmonique de surface</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In retrospective observational studies, an increased relative risk of incident narcolepsy was observed in some European countries among recipients of the AS03-adjuvanted, A(H1N1)pdm09, inactivated, detergent-split virion vaccine Pandemrix™ manufactured in Dresden, Germany (D-Pan H1N1). A similar increased risk was not observed in a retrospective population-based study in individuals in Quebec province, Canada, who received Aprepanrix™, a Quebec-manufactured AS03-adjuvanted A(H1N1)pdm09 inactivated, detergent-split virion vaccine (Q-Pan H1N1). Antibody responses in D-Pan versus Q-Pan vaccinees (adults/children) measured as hemagglutination inhibition (HI) titers 21 d post-vaccination were found to be equivalent (NCT01161160). The current post-hoc analysis was conducted to determine whether antibody avidity differed following immunization with the 2 vaccines. Using surface plasmon resonance, we evaluated the capacity of serum specimens (drawn from the comparative immunogenicity trial) from a subset of subjects aged 3-9 y who received either D-Pan or Q-Pan (N = 28/group), to bind to recombinant A(H1N1)pdm09 hemagglutinin. IgG antibodies were purified from Day 21 sera. Binding was assessed by end association level; dissociation by retention of antigen-antibody complexes at the end of the dissociation phase, and kd. Inter-run variability for the control monoclonal antibody, association levels and dissociation levels was low (CVs 1.3%, 7.8% and 1.4%, respectively); non-specific binding was negligible. High avidity and slow dissociation was observed for both groups (kd ≤ 10(-4)/s; geometric mean [IQR] association and dissociation levels for D-Pan/Q-Pan: 15.4 RU [13.4-17.7]/12.4 RU [10.8-14.3] and 94.5% [92.5-96.5]/95.5% [93.5-97.6], respectively). Association, but not dissociation levels correlated with HI titers. No significant differences in avidity parameters were observed between D-Pan and Q-Pan sera.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27105343</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.</ArticleTitle><Pagination><MedlinePgn>2289-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2016.1168954</ELocationID><Abstract><AbstractText>In retrospective observational studies, an increased relative risk of incident narcolepsy was observed in some European countries among recipients of the AS03-adjuvanted, A(H1N1)pdm09, inactivated, detergent-split virion vaccine Pandemrix™ manufactured in Dresden, Germany (D-Pan H1N1). A similar increased risk was not observed in a retrospective population-based study in individuals in Quebec province, Canada, who received Aprepanrix™, a Quebec-manufactured AS03-adjuvanted A(H1N1)pdm09 inactivated, detergent-split virion vaccine (Q-Pan H1N1). Antibody responses in D-Pan versus Q-Pan vaccinees (adults/children) measured as hemagglutination inhibition (HI) titers 21 d post-vaccination were found to be equivalent (NCT01161160). The current post-hoc analysis was conducted to determine whether antibody avidity differed following immunization with the 2 vaccines. Using surface plasmon resonance, we evaluated the capacity of serum specimens (drawn from the comparative immunogenicity trial) from a subset of subjects aged 3-9 y who received either D-Pan or Q-Pan (N = 28/group), to bind to recombinant A(H1N1)pdm09 hemagglutinin. IgG antibodies were purified from Day 21 sera. Binding was assessed by end association level; dissociation by retention of antigen-antibody complexes at the end of the dissociation phase, and kd. Inter-run variability for the control monoclonal antibody, association levels and dissociation levels was low (CVs 1.3%, 7.8% and 1.4%, respectively); non-specific binding was negligible. High avidity and slow dissociation was observed for both groups (kd ≤ 10(-4)/s; geometric mean [IQR] association and dissociation levels for D-Pan/Q-Pan: 15.4 RU [13.4-17.7]/12.4 RU [10.8-14.3] and 94.5% [92.5-96.5]/95.5% [93.5-97.6], respectively). Association, but not dissociation levels correlated with HI titers. No significant differences in avidity parameters were observed between D-Pan and Q-Pan sera.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canelle</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>a GSK Vaccines , Rixensart , Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewé</LastName><ForeName>Walthère</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>a GSK Vaccines , Rixensart , Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Innis</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>a GSK Vaccines , Rixensart , Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Most</LastName><ForeName>Robbert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>a GSK Vaccines , Rixensart , Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568072">arepanrix</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556153">pandemrix</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000915" MajorTopicYN="Y">Antibody Affinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N">Quebec</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">AS03</Keyword><Keyword MajorTopicYN="Y">Arepanrix</Keyword><Keyword MajorTopicYN="Y">H1N1</Keyword><Keyword MajorTopicYN="Y">Pandemrix</Keyword><Keyword MajorTopicYN="Y">antibody</Keyword><Keyword MajorTopicYN="Y">avidity</Keyword><Keyword MajorTopicYN="Y">hemagglutinin</Keyword><Keyword MajorTopicYN="Y">immunogenicity</Keyword><Keyword MajorTopicYN="Y">narcolepsy</Keyword><Keyword MajorTopicYN="Y">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27105343</ArticleId><ArticleId IdType="doi">10.1080/21645515.2016.1168954</ArticleId><ArticleId IdType="pmc">PMC5027709</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Cell Probes. 2012 Apr;26(2):73-80</Citation><ArticleIdList><ArticleId IdType="pubmed">22285687</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2015 Jul 1;7(294):294ra105</Citation><ArticleIdList><ArticleId IdType="pubmed">26136476</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2012 Jul;19(7):1012-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22573737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2014 Sep 11;19(36):null</Citation><ArticleIdList><ArticleId IdType="pubmed">25232921</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1966 May;37(5):715-27</Citation><ArticleIdList><ArticleId IdType="pubmed">4956666</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2011 Feb;17(2):195-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21131958</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2015 Jul;47:44-57</Citation><ArticleIdList><ArticleId IdType="pubmed">25452148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2014 May;50:1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">24559657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 2014 Feb;404:1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24316020</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2012 Feb 15;205(4):610-20</Citation><ArticleIdList><ArticleId IdType="pubmed">22207649</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Aug 1;208(3):413-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23633404</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2010 Jun;9(6):645-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20518719</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Sep 29;9(9):e108489</Citation><ArticleIdList><ArticleId IdType="pubmed">25264897</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 2006 May 15;352(2):208-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16564019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2014;10(3):572-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24342916</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2011 Jun 1;3(85):85ra48</Citation><ArticleIdList><ArticleId IdType="pubmed">21632986</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Dec 15;9(12):e115126</Citation><ArticleIdList><ArticleId IdType="pubmed">25506706</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2013 Sep 16;13:435</Citation><ArticleIdList><ArticleId IdType="pubmed">24041010</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 1994 Jun;43(2):119-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8083659</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Today. 1981 Jul;2(7):134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25289455</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1999 May;67(5):2366-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10225896</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2010 Jan 20;2(15):15ra5</Citation><ArticleIdList><ArticleId IdType="pubmed">20371470</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Feb 6;31(8):1246-54</Citation><ArticleIdList><ArticleId IdType="pubmed">23246544</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Jul 31;32(35):4550-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24950357</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012 Jan 26;17(4):null</Citation><ArticleIdList><ArticleId IdType="pubmed">22297139</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2011 Dec;21(6):897-903</Citation><ArticleIdList><ArticleId IdType="pubmed">21963829</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2015 Mar;157(1):91-101</Citation><ArticleIdList><ArticleId IdType="pubmed">25543089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Jun 1;201(11):1644-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20423222</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Dec 15;9(12):e114361</Citation><ArticleIdList><ArticleId IdType="pubmed">25501681</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1997 Jun 27;276(5321):2024-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9197261</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2002 Jan 15;34(2):191-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11740707</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2004 Jun;72(6):3451-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15155652</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li></country></list><tree><country name="Belgique"><noRegion><name sortKey="Canelle, Quentin" sort="Canelle, Quentin" uniqKey="Canelle Q" first="Quentin" last="Canelle">Quentin Canelle</name></noRegion><name sortKey="Dewe, Walthere" sort="Dewe, Walthere" uniqKey="Dewe W" first="Walthère" last="Dewé">Walthère Dewé</name><name sortKey="Innis, Bruce L" sort="Innis, Bruce L" uniqKey="Innis B" first="Bruce L" last="Innis">Bruce L. Innis</name><name sortKey="Van Der Most, Robbert" sort="Van Der Most, Robbert" uniqKey="Van Der Most R" first="Robbert" last="Van Der Most">Robbert Van Der Most</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000157 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000157 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27105343
|texte= Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27105343" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |